Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-08
2005-02-08
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S336000, C514S300000, C549S009000, C546S279700, C546S122000
Reexamination Certificate
active
06852753
ABSTRACT:
Thiepine apical sodium co-dependent bile acid transport (ASBT) inhibitors are disclosed together with methods of making the same, methods of using the same to treat hyperlipidemic conditions as well as pharmaceutical compositions containing the same compounds.
REFERENCES:
patent: 3262850 (1966-07-01), Glynne
patent: 3287370 (1966-11-01), Mohrbacher
patent: 3389144 (1968-06-01), Mohrbacher
patent: 3520891 (1970-07-01), Mohrbacher
patent: 3674836 (1972-07-01), Creger
patent: 3692895 (1972-09-01), Nelson
patent: 3694446 (1972-09-01), Houlhan et al.
patent: 3714190 (1973-01-01), Boissier
patent: 3781328 (1973-12-01), Witte
patent: 3948973 (1976-04-01), Phillips
patent: 3962261 (1976-06-01), Zinnes
patent: 3972878 (1976-08-01), Schirmann
patent: 3983140 (1976-09-01), Endo
patent: 4002750 (1977-01-01), Ambrogi
patent: 4058552 (1977-11-01), Mieville
patent: 4185109 (1980-01-01), Rosen
patent: 4231938 (1980-11-01), Monaghan
patent: 4251526 (1981-02-01), McCall
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4410629 (1983-10-01), Terahara et al.
patent: 4444784 (1984-04-01), Hoffman
patent: 4448979 (1984-05-01), Terahara et al.
patent: 4559332 (1985-12-01), Grob et al.
patent: 5075293 (1991-12-01), Reifschneider
patent: 5153184 (1992-10-01), Reifschneider
patent: 5158943 (1992-10-01), Sohda et al.
patent: 5244887 (1993-09-01), Straub
patent: 5260316 (1993-11-01), Van Duzer
patent: 5334600 (1994-08-01), Van Duzer
patent: 5350761 (1994-09-01), Van Duzer
patent: 5354772 (1994-10-01), Kathawala
patent: 5430116 (1995-07-01), Kramer
patent: 5502045 (1996-03-01), Miettinen
patent: 5512558 (1996-04-01), Enhsen
patent: 5519001 (1996-05-01), Rampratap
patent: 5602152 (1997-02-01), Berthelon
patent: 5610151 (1997-03-01), Glombik
patent: 5663165 (1997-09-01), Brieaddy
patent: 5703188 (1997-12-01), Mandeville
patent: 5705524 (1998-01-01), McGee
patent: 5723458 (1998-03-01), Brieaddy
patent: 5767115 (1998-06-01), Rosenblum
patent: 5811450 (1998-09-01), Bischofberger et al.
patent: 5929062 (1999-07-01), Haines
patent: 5994391 (1999-11-01), Lee et al.
patent: 6020330 (2000-02-01), Enhsen et al.
patent: 6034118 (2000-03-01), Bischofberger et al.
patent: A-3020992 (1992-12-01), None
patent: A-6194694 (1994-06-01), None
patent: A-6194894 (1994-06-01), None
patent: A-6194994 (1994-06-01), None
patent: 2025294 (1991-03-01), None
patent: 2078588 (1993-03-01), None
patent: 2085782 (1993-06-01), None
patent: 2085830 (1993-06-01), None
patent: 1211258 (1968-02-01), None
patent: 3 122 499 (1990-05-01), None
patent: 196 27 430 (1996-08-01), None
patent: 0 022 487 (1981-01-01), None
patent: 0 244 364 (1981-04-01), None
patent: 0 067 086 (1982-10-01), None
patent: 0 129 748 (1985-02-01), None
patent: 0 033 538 (1985-11-01), None
patent: 0 250 265 (1987-06-01), None
patent: 0 338 331 (1989-06-01), None
patent: 0 379 161 (1990-01-01), None
patent: 0 409 281 (1991-01-01), None
patent: 0 531 901 (1992-02-01), None
patent: 0 508 425 (1992-09-01), None
patent: 0 549 967 (1992-12-01), None
patent: 0 526 402 (1993-02-01), None
patent: 0 559 064 (1993-02-01), None
patent: 0 563 731 (1993-03-01), None
patent: 0 568 898 (1993-04-01), None
patent: 0 818 197 (1997-06-01), None
patent: 0 818 448 (1997-06-01), None
patent: 0 796 846 (1997-07-01), None
patent: 0 801 060 (1997-10-01), None
patent: 2 661 676 (1990-02-01), None
patent: 1 211 258 (1970-11-01), None
patent: 2 077 264 (1981-12-01), None
patent: 2 305 665 (1997-04-01), None
patent: 2 329 334 (1999-03-01), None
patent: 10-287662 (1998-10-01), None
patent: 8901477 (1989-02-01), None
patent: 9108205 (1991-06-01), None
patent: 9217467 (1992-10-01), None
patent: 9218115 (1992-10-01), None
patent: 9218462 (1992-10-01), None
patent: 9316055 (1993-08-01), None
patent: 9321146 (1993-10-01), None
patent: 9418183 (1994-08-01), None
patent: 9418184 (1994-08-01), None
patent: 9424087 (1994-10-01), None
patent: 9521843 (1995-08-01), None
patent: 9605188 (1996-02-01), None
patent: 9608484 (1996-03-01), None
patent: 9616051 (1996-05-01), None
patent: 9640255 (1996-12-01), None
patent: 9703953 (1997-02-01), None
patent: 9733882 (1997-09-01), None
patent: 9749387 (1997-12-01), None
patent: 9749736 (1997-12-01), None
patent: 9802432 (1998-01-01), None
patent: 9806405 (1998-02-01), None
patent: 9823593 (1998-06-01), None
patent: 9835937 (1998-08-01), None
patent: WO 9838182 (1998-09-01), None
patent: 9838182 (1998-09-01), None
patent: 9839299 (1998-09-01), None
patent: 9840375 (1998-09-01), None
patent: WO 9840375 (1998-09-01), None
patent: 9856757 (1998-12-01), None
patent: 9911259 (1999-03-01), None
patent: 9911260 (1999-03-01), None
patent: 9911263 (1999-03-01), None
patent: 9914174 (1999-03-01), None
patent: 9914204 (1999-03-01), None
patent: 9914215 (1999-03-01), None
patent: 9932478 (1999-07-01), None
patent: 9935135 (1999-07-01), None
patent: 9964409 (1999-12-01), None
patent: 0035889 (2000-06-01), None
Angelin, B., “Regulation of Hepatic Cholesterol Metabolism in Man,” Ann. Med. 23, pp. 10-27 (1991).
Blum, C. B., “Comparison of Properties of Four Inhibitors of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase,” Am. J. Cardiol., 73(14), 3D-11D, (1994).
Cayen, M.N., “Dispositi9n, Metabolism and Pharmacokinetics of Anthyperlipidemic Agents in Laboratory Animals and Man,” Pharmac. & Ther., 29, pp. 157-204 (1985).
Da Col, et al., “Tolerability and Efficacy of Combination Therapy with Simvastatin Plus Gemfibroail in Type II Refractory Familial Combined Hyperlipidemia,” Curr. Therap. Research, vol. 53, No. 5, pp. 473-483 (1993).
Davignon, et al. “HMG CoA Reductase Inhibitors: A look back and a look ahead,” Can. J. Cardiol., 8(8), pp. 843-864 (1992).
Endo, A. “Chemistry, biochemistry and pharmacology of HMG-Co-A reductase inhibitors,” Klin. Wochemschr. 66, pp. 421-427 (1988).
Kramer et al., “Bile acid derived HMG-CoA reductase inhibitors,” Biochimica dt Biophysica Acta, 1227 pp. 137-154 (1994).
Marcus, A., “Role of the HMG-CoA Reductase Inhibitiors in the Treatment of Dyslipidemia: An Evolutionary Review,” CVR&R, pp. 13-27 (Jan. 1996).
International Search Report PCT/US03/00025, Issued Sep. 5, 2003.
A. Barrett et al., “Total Synthesis and Stereochemical Assignment of the Quinquecyclopropane-Containing Cholesteryl Ester Transfer Protein Inhibitor U-106305”, J. Am Chem. Soc., 1996, 118, pp. 7863-7864.
P. Barter et al. “High Density Lipoproteins and Coronary Heart Disease”, Atherosclerosis, 121 1996, pp. 1-12.
A. Beckwith et al., “Iododediazoniation of Arenediazonium Salts Accompanied by Aryl Radical Ring Closure” J. Org. Chem. 1987, vol. 52, pp. 1922-1930.
D. Bilheimer et al., “Mevinolin and Colestipol Stimulate Receptor-Mediated Clearance of Low Density Lipoprotein From Plasma In Familial Hypercholesterolemia Heterzygotes”, Proc. Natl. Acad. Sci. USA, vol. 80, Jul. 1983, pp. 4124-4128.
C. Bisgaier et al., Cholesteryl Ester Transfer Protein Inhibition By PD 140195, Lipids, vol. 29, No. 12, 1994, pp. 811-818.
D. Blankenhorn et al., “Beneficial Effects of Combined Colestipol-Niacin Therapy On Coronary Atherosclerosis and Coronary Venous Bypass Grafts”, JAMA, Jun. 19, 1987, vol. 257, No. 23, pp. 3233-3240.
D. Blankenhorn et al., “Beneficial Effects of Colestipol-Niacin Therapy on the Common Carotid Artery” Circulation vol. 88, Jul. 1, 1993, pp. 20-28.
P. Bonin et al., “A Peptide Inhibitor Of Cholesteryl Ester Transfer Protein Identified By Screening a Bacteriophage Display Library”, Journal of Peptide Research, 51, 1998, pp. 216-225.
G. Brown, et al., “Regression of Coronary Artery Disease As A Result of Intensive Lipid-Lowering Therapy in Men With High Levels Of Apolipoprotein B”, The New England Journal of Medicine, vol. 323, Nov. 8, 1990, No. 19, pp. 1289-1339.
M. Brown et al., Induction of 3-hydroxy-3Methylglutaryl Coenzyme A Reductase Activity in Human Fibroblasts Incubated with Compactin (ML-236B), A Competitive Inhibitor of the Reductase, The Journal of
Koeller Kevin J.
Tremont Samuel J.
Harness & Dickey & Pierce P.L.C.
Lambkin Deborah C.
Pharmacia Corporation
LandOfFree
Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3456422